K.u. Leuven Research & Development

Universiteit Gent

Laboratoire Theramex S.a.

Ire-medgenix S.a.

Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw

D. Collen Research Foundation Vzw

Roger Bouillon

Maurits E Vandewalle

Pierre Jean De Clercq

Annemieke Verstuyf

Pierre Eliard

Peter Carmeliet

Désiré Collen

Mark Waer

Pierre J De Clercq

Chantal Mathieu

Wim Schepens

Gertrudis Carmeliet

Maurits Vanderwalle

Pierre J De Clerco

Novel vitamin D analogues are useful for making pharmaceutical compositions for the prevention or treatment of bone disorders such as osteoporosis.

[object Object]

The present invention relates to 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, compositions which comprise said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, and methods for treating diseases, illnesses, and the like with said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes.

7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes

This invention relates to antagonists of placental growth factor and signalling thereof, pharmaceutical compositions containing such antagonists and the use of such antagonists to prevent bone loss or bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass and/or bone defects in vertebrates, and particularly mammals, including humans.

Placental growth factor as a target for the treatment of osteoporosis

Structural analogues of vitamin D

A method for modulating the immune system by administering one or more vitamin D (analogues) to a subject in need of immune therapy, which method may (but need not) include simultaneous treatment with a second immune system modulating active agent. Preferably, the treatment method is used to induce primary or secondary prevention of type I diabetes in a subject susceptible to type I diabetes. Administration of the vitamin D (analogues) is enteral or parenteral.

Methods and compositions for primary and secondary prevention of

Vitamin D derivatives corresponding to the following formula I ##STR1## in which R.sub.1 denotes a substituted alkyl group having 1 to 15 carbon atoms, in particular the side chains of vitamin D.sub.2 (C.sup.20 to C.sup.28) or D.sub.3 (C.sup.20 to C.sup.27), or these same chains partially modified,

Vitamin D derivatives: therapeutic applications and applications to

Growing community of inventors

Herent, Belgium

Roger Bouillon